Successful coronary stenting in a patient with factor V deficiency in the absence of fresh frozen plasma transfusion: Case report.
|Abstract||Drug-eluting stent (DES) implantation in a patient with factor V deficiency (F5D) is very complex. No antithrombotic therapy study has been reported for F5D patients who undergo a coronary stenting procedure.|
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
|Publication Year Start||2018-01-01|
PMID- 29390379 OWN - NLM STAT- MEDLINE DCOM- 20180212 LR - 20180212 IS - 1536-5964 (Electronic) IS - 0025-7974 (Linking) VI - 96 IP - 50 DP - 2017 Dec TI - Successful coronary stenting in a patient with factor V deficiency in the absence of fresh frozen plasma transfusion: Case report. PG - e9274 LID - 10.1097/MD.0000000000009274 [doi] AB - RATIONALE: Drug-eluting stent (DES) implantation in a patient with factor V deficiency (F5D) is very complex. No antithrombotic therapy study has been reported for F5D patients who undergo a coronary stenting procedure. PATIENT CONCERNS: A 73-year-old woman presented with chest discomfort and exertional dyspnea. Coronary stenting was performed successfully using DES stents. DIAGNOSES: The D-dimer, prothrombin time, and partial thromboplastin time prolongation persisted from admission until 24 hours after coronary stenting. Epistaxis and blood-tinged sputum occurred on day 3. The antiplatelet therapy measured using a Multiplate Analyzer was adequate, and other laboratory findings except factor V activity (14%) were within normal ranges; she was diagnosed with F5D based on low factor V activity. INTERVENTIONS: While taking 90 mg of ticagrelor and 100 mg of aspirin daily, the patient revisited due to recurrent epistaxis, hemoptysis, and coughing on day 26. Epistaxis and hemoptysis stopped after the aspirin was discontinued. Finally, the daily maintenance dose was reduced to 90 mg of ticagrelor once. OUTCOMES: She led healthy life for 9 months without any recurrent symptoms and the test results also were stabilized. LESSONS: We report a case of an F5D patient who underwent coronary stenting in the absence of frozen fresh plasma transfusion who received successful maintenance therapy using a single antiplatelet agent (90 mg of ticagrelor/day) with recurrent multiple mucosal bleeding events after coronary stenting. CI - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved. FAU - Choi, Seongil AU - Choi S FAU - Song, MooKon AU - Song M LA - eng PT - Case Reports PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (Purinergic P2Y Receptor Antagonists) RN - GLH0314RVC (Ticagrelor) RN - K72T3FS567 (Adenosine) SB - AIM SB - IM MH - Adenosine/*analogs & derivatives/therapeutic use MH - Aged MH - Blood Coagulation Tests MH - Coronary Stenosis/diagnosis/*drug therapy MH - *Drug-Eluting Stents MH - Factor V Deficiency/*complications MH - Female MH - Humans MH - Purinergic P2Y Receptor Antagonists/*therapeutic use EDAT- 2018/02/03 06:00 MHDA- 2018/02/13 06:00 CRDT- 2018/02/03 06:00 PHST- 2018/02/03 06:00 [entrez] PHST- 2018/02/03 06:00 [pubmed] PHST- 2018/02/13 06:00 [medline] AID - 10.1097/MD.0000000000009274 [doi] AID - 00005792-201712150-00129 [pii] PST - ppublish SO - Medicine (Baltimore). 2017 Dec;96(50):e9274. doi: 10.1097/MD.0000000000009274.